Also, more detailed standardization and agreements regarding the workflow proved necessary, for example which minimal set of genes to test for in addition to BRCA1 and BRCA2. The tumor DNA test has to be expanded to include other OC risk genes, as healthcare professionals and other studies (e.g., [23]) have expressed concerns about solely testing for pathogenic variants in BRCA1 and BRCA2. National agreements and guidelines should be established, and the balance between reducing and allowing variation between centers has to be carefully considered. This evidence concerns the gene BRCA2 and neoplasm.